Consequently, GLP‐1 RAs are now in advanced clinical development for the treatment of chronic kidney disease, broader cardiovascular risk reduction, metabolic liver disease and Alzheimer's disease. The gene discussed is GLP1R; the disease is Alzheimer disease.